Care Until Cure

The Care until Cure Research Program was established in the year 2000 in collaboration with Wyeth Canada, now Pfizer. Pfizer Canada strives every day to help Canadians live healthy, balanced lives. They do that by discovering and developing innovative medicines. As a company, They're dedicated to building healthier communities and empowering Canadians to make healthier choices every day. At Pfizer Canada, they believe that to be truly healthy, it takes more than medication.

This program allows Canadian investigators to conduct research on various medical and psychosocial aspects of bleeding disorders. Grants are given for clinical research, including outcome evaluation, in fields relevant to improving the quality of life of persons with hemophilia, persons with von Willebrand disease or other inherited bleeding disorders, persons with related conditions such as HIV or hepatitis C as well as carriers of an inherited bleeding disorder.

Please note that the CHS will not be accepting new applications at this time for the year 2012-13. The funds have been earmarked for second year projects which began in 2011. Should new funds become available for 2012, a call for new applications will be issued.

For the 2011-2012 edition of the program, specific areas of interest were identified and investigators, where possible, were encouraged to submit proposals within these areas. While the grants review committee continued to allocate funding to the strongest and most relevant projects, preference was given to those projects which corresponded to the areas of interest listed below.

2011-2012 AREAS OF INTEREST:
Hemophilia B:
1. Epidemiology / burden of disease / outcome research
2. Routine prophylaxis and preventative treatment
3. Surgical prophylaxis, dosing
4. Recovery experience (hemophilia B)
5. Joint outcomes and optimizing therapy
Transition and clinical issues:
1. Treatment adherence to prescribed regiments
2. Management of adolescent hemophilia patients
3. Management of aging hemophilia population
Clinical monitoring of hemophilia treatment
Product switching experience:
1. Rationale for switching products
2. Inhibitor development and safety associated with switches
Inhibitors
Factor VIII molecule
Antifibrinolytics